Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Wachovia Ups Biogen Idec to 'Outperform'


Wachovia upgraded Biogen Idec (BIIB) to outperform from market perform. Yesterday the company and Elan (ELN) said they expect to submit an application to FDA for approval of Antegren by mid-2004.

Wachovia analyst Martin Auster says the mid-2004 filing would set up an end of 2004 to early 2005 launch, 1 year ahead of his expectation. He says the filing is based on 1 year of relapse data, rather than more common 2-year period, which implies superior treatment experience.

Auster sees $130 million in Antegren sales in 2005, reaching $941 million in 2008. He says Biogen Idec will be one of the few large-cap biotechs with accelerating EPS trends over the next few years.

He ups his $41 to $46 valuation range to $60 to $64. He sees EPS of $1.24 in 2004.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus